Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Tetra-arsenic tetra-sulfide (As4S4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein

verfasst von: Yanfeng Liu, Pengcheng He, Feng Liu, Naicen Zhou, Xiaoyan Cheng, Lili Shi, Huachao Zhu, Jing Zhao, Yuan Wang, Mei Zhang

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Tetra-arsenic tetra-sulfide (As4S4) is an arsenic compound with antitumor activity, especially in acute promyelocytic leukemia (APL) that are resistant to retinoic acid (RA). Although recent studies have revealed that the therapeutic action of As4S4 is closely associated with the induction of cellular apoptosis, the exact molecular mechanism underlying this action in RA-resistant APL remains to be clarified. In this study, we found that As4S4-induced apoptosis was accompanied by reduced mRNA and protein expression of SET gene in RA-resistant NB4-R1 cells. Moreover, RNAi knockdown of SET gene further promoted As4S4-induced apoptosis, while SET overexpression recovered the cell viability, suggesting that As4S4 induces apoptosis through the reduction of SET protein in NB4-R1 cells. We also observed that the knockdown of SET gene resulted in the upregulation of protein phosphatase 2 (PP2A) expression and the downregulation of promyelocytic leukemia and retinoic acid receptor α fusion gene (PML-RARα) expression, which were enhanced by As4S4 treatments. By contrast, overexpression of SET gene resulted in PP2A downregulation and PML-RARα upregulation, which were abolished by As4S4 pretreatment. Since PP2A is a proapoptotic factor and PML-RARα is an antiapoptotic factor, our results suggest that As4S4-induced apoptosis in RA-resistant NB4-R1 cells is through the downregulation of SET protein expression, which, in turn, increases PP2A and reduces PML-RARα expressions to lead to cell apoptosis.
Literatur
1.
Zurück zum Zitat Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–15.PubMedCrossRef Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505–15.PubMedCrossRef
2.
Zurück zum Zitat Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:463–82.PubMedCrossRef Falanga A, Rickles FR. Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2003;16:463–82.PubMedCrossRef
3.
Zurück zum Zitat Mattson JC. Acute promyelocytic leukemia. From morphology to molecular lesions. Clin Lab Med. 2000;20:83–103. ix.PubMed Mattson JC. Acute promyelocytic leukemia. From morphology to molecular lesions. Clin Lab Med. 2000;20:83–103. ix.PubMed
4.
Zurück zum Zitat Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 2010;17:173–85.PubMedCrossRef Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, et al. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell. 2010;17:173–85.PubMedCrossRef
5.
Zurück zum Zitat Kamimura T, Miyamoto T, Harada M, Akashi K. Advances in therapies for acute promyelocytic leukemia. Cancer Sci. 2011;102:1929–37.PubMedCrossRef Kamimura T, Miyamoto T, Harada M, Akashi K. Advances in therapies for acute promyelocytic leukemia. Cancer Sci. 2011;102:1929–37.PubMedCrossRef
6.
Zurück zum Zitat Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21.PubMedCrossRef Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111–21.PubMedCrossRef
7.
Zurück zum Zitat Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20:7140–5.PubMedCrossRef Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20:7140–5.PubMedCrossRef
8.
Zurück zum Zitat Breccia M, Lo-Coco F. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother. 2012;13:1031–43.PubMedCrossRef Breccia M, Lo-Coco F. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother. 2012;13:1031–43.PubMedCrossRef
9.
Zurück zum Zitat Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73:1116–22.PubMed Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood. 1989;73:1116–22.PubMed
10.
Zurück zum Zitat Hoffman E, Mielicki WP. All-trans retinoic acid (ATRA) in prevention and cancer therapy. Postepy Hig Med Dosw (Online). 2010;64:284–90. Hoffman E, Mielicki WP. All-trans retinoic acid (ATRA) in prevention and cancer therapy. Postepy Hig Med Dosw (Online). 2010;64:284–90.
11.
Zurück zum Zitat Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504–10.PubMedCrossRef Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504–10.PubMedCrossRef
12.
Zurück zum Zitat Holmes D, Vishnu P, Dorer RK, Aboulafia DM. All-trans retinoic acid-induced pseudotumor cerebri during induction therapy for acute promyelocytic leukemia: a case report and literature review. Case Rep Oncol Med. 2012;2012:313057.PubMedCentralPubMed Holmes D, Vishnu P, Dorer RK, Aboulafia DM. All-trans retinoic acid-induced pseudotumor cerebri during induction therapy for acute promyelocytic leukemia: a case report and literature review. Case Rep Oncol Med. 2012;2012:313057.PubMedCentralPubMed
13.
Zurück zum Zitat Zayed A, Couban S, Hayne O, Sparavalo N, Shawwa A, Sadek I, et al. Acute promyelocytic leukemia: a novel PML/RARalpha fusion that generates a frameshift in the RARalpha transcript and ATRA resistance. Leuk Lymphoma. 2007;48:489–96.PubMedCrossRef Zayed A, Couban S, Hayne O, Sparavalo N, Shawwa A, Sadek I, et al. Acute promyelocytic leukemia: a novel PML/RARalpha fusion that generates a frameshift in the RARalpha transcript and ATRA resistance. Leuk Lymphoma. 2007;48:489–96.PubMedCrossRef
14.
Zurück zum Zitat Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052–61.PubMed Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88:1052–61.PubMed
15.
Zurück zum Zitat Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–32.PubMedCrossRef Mathews V, George B, Lakshmi KM, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627–32.PubMedCrossRef
16.
Zurück zum Zitat Mathews V, Chendamarai E, George B, Viswabandya A, Srivastava A. Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis. 2011;3:e2011056.PubMedCentralPubMedCrossRef Mathews V, Chendamarai E, George B, Viswabandya A, Srivastava A. Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide. Mediterr J Hematol Infect Dis. 2011;3:e2011056.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Wang FR, Lou YQ, Lu DP. A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia. Zhonghua Nei Ke Za Zhi. 2005;44:730–3.PubMed Wang FR, Lou YQ, Lu DP. A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia. Zhonghua Nei Ke Za Zhi. 2005;44:730–3.PubMed
18.
Zurück zum Zitat Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99:3136–43.PubMedCrossRef Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99:3136–43.PubMedCrossRef
19.
Zurück zum Zitat Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104:4219–25.PubMedCrossRef Yin T, Wu YL, Sun HP, Sun GL, Du YZ, Wang KK, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104:4219–25.PubMedCrossRef
20.
Zurück zum Zitat Teng ZP, Zhang P, Zhu HH, Hao HY, Qin XY, Hao L, et al. Mechanism of tetra-arsenic tetra-sulfide in inducing apoptosis of acute promyelocytic leukemia cells. Beijing Da Xue Xue Bao. 2006;38:236–8.PubMed Teng ZP, Zhang P, Zhu HH, Hao HY, Qin XY, Hao L, et al. Mechanism of tetra-arsenic tetra-sulfide in inducing apoptosis of acute promyelocytic leukemia cells. Beijing Da Xue Xue Bao. 2006;38:236–8.PubMed
21.
Zurück zum Zitat Wang JZ, Liu YR, Qin YZ, Jiang H, Wang FR, Bao L, et al. Change of PML/PML-RARalpha protein during treatment with tetraarsenic tetrasulfide (As4S4) in patients with acute promyelocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11:464–8.PubMed Wang JZ, Liu YR, Qin YZ, Jiang H, Wang FR, Bao L, et al. Change of PML/PML-RARalpha protein during treatment with tetraarsenic tetrasulfide (As4S4) in patients with acute promyelocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003;11:464–8.PubMed
22.
Zurück zum Zitat Qi J, He P, Chen W, Wang H, Wang X, Zhang M. Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells. Leuk Res. 2010;34:1506–16.PubMedCrossRef Qi J, He P, Chen W, Wang H, Wang X, Zhang M. Comparative proteome study of apoptosis induced by As4S4 in retinoid acid resistant human acute promyelocytic leukemia NB4-R1 cells. Leuk Res. 2010;34:1506–16.PubMedCrossRef
23.
24.
Zurück zum Zitat Tallman MS. What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol. 2008;21:659–66.PubMedCrossRef Tallman MS. What is the role of arsenic in newly diagnosed APL? Best Pract Res Clin Haematol. 2008;21:659–66.PubMedCrossRef
25.
Zurück zum Zitat Balaz P, Sedlak J. Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview). Toxins (Basel). 2010;2:1568–81.PubMedCentralPubMedCrossRef Balaz P, Sedlak J. Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview). Toxins (Basel). 2010;2:1568–81.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Ye HQ, Gan L, Yang XL, Xu HB. Membrane toxicity accounts for apoptosis induced by realgar nanoparticles in promyelocytic leukemia HL-60 cells. Biol Trace Elem Res. 2005;103:117–32.PubMedCrossRef Ye HQ, Gan L, Yang XL, Xu HB. Membrane toxicity accounts for apoptosis induced by realgar nanoparticles in promyelocytic leukemia HL-60 cells. Biol Trace Elem Res. 2005;103:117–32.PubMedCrossRef
27.
Zurück zum Zitat Wang XB, Gao HY, Hou BL, Huang J, Xi RG, Wu LJ. Nanoparticle realgar powders induce apoptosis in U937 cells through caspase MAPK and mitochondrial pathways. Arch Pharm Res. 2007;30:653–8.PubMedCrossRef Wang XB, Gao HY, Hou BL, Huang J, Xi RG, Wu LJ. Nanoparticle realgar powders induce apoptosis in U937 cells through caspase MAPK and mitochondrial pathways. Arch Pharm Res. 2007;30:653–8.PubMedCrossRef
28.
Zurück zum Zitat Tse WP, Cheng CH, Che CT, Zhao M, Fan RQ, Lin ZX. Realgar-mediated growth inhibition on HaCaT human keratinocytes is associated with induction of apoptosis. Int J Mol Med. 2009;24:189–96.PubMed Tse WP, Cheng CH, Che CT, Zhao M, Fan RQ, Lin ZX. Realgar-mediated growth inhibition on HaCaT human keratinocytes is associated with induction of apoptosis. Int J Mol Med. 2009;24:189–96.PubMed
29.
Zurück zum Zitat Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M. The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem. 2002;277:25026–31.PubMedCrossRef Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M. The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem. 2002;277:25026–31.PubMedCrossRef
30.
Zurück zum Zitat Santa-Coloma TA. Anp32e (Cpd1) and related protein phosphatase 2 inhibitors. Cerebellum. 2003;2:310–20.PubMedCrossRef Santa-Coloma TA. Anp32e (Cpd1) and related protein phosphatase 2 inhibitors. Cerebellum. 2003;2:310–20.PubMedCrossRef
31.
Zurück zum Zitat Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996;271:11059–62.PubMedCrossRef Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem. 1996;271:11059–62.PubMedCrossRef
32.
Zurück zum Zitat Adler HT, Nallaseth FS, Walter G, Tkachuk DC. HRX leukemic fusion proteins form a heterocomplex with the leukemia-associated protein SET and protein phosphatase 2A. J Biol Chem. 1997;272:28407–14.PubMedCrossRef Adler HT, Nallaseth FS, Walter G, Tkachuk DC. HRX leukemic fusion proteins form a heterocomplex with the leukemia-associated protein SET and protein phosphatase 2A. J Biol Chem. 1997;272:28407–14.PubMedCrossRef
33.
Zurück zum Zitat Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, et al. SET complex in serous epithelial ovarian cancer. Int J Cancer. 2006;119:2119–26.PubMedCrossRef Ouellet V, Le Page C, Guyot MC, Lussier C, Tonin PN, Provencher DM, et al. SET complex in serous epithelial ovarian cancer. Int J Cancer. 2006;119:2119–26.PubMedCrossRef
34.
Zurück zum Zitat Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol. 1998;9:1873–80.PubMed Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ. Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol. 1998;9:1873–80.PubMed
35.
Zurück zum Zitat Fornerod M, Boer J, van Baal S, Jaeglé M, von Lindern M, Murti KG, et al. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene. 1995;10:1739–48.PubMed Fornerod M, Boer J, van Baal S, Jaeglé M, von Lindern M, Murti KG, et al. Relocation of the carboxyterminal part of CAN from the nuclear envelope to the nucleus as a result of leukemia-specific chromosome rearrangements. Oncogene. 1995;10:1739–48.PubMed
36.
Zurück zum Zitat Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ, et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2012;97:543–50.PubMedCentralPubMedCrossRef Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, García-Sánchez MA, Calasanz MJ, et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica. 2012;97:543–50.PubMedCentralPubMedCrossRef
37.
Zurück zum Zitat Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001;353:417–39.PubMedCentralPubMedCrossRef Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J. 2001;353:417–39.PubMedCentralPubMedCrossRef
38.
Zurück zum Zitat Janssens V, Rebollo A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med. 2012;12:268–87.PubMedCrossRef Janssens V, Rebollo A. The role and therapeutic potential of Ser/Thr phosphatase PP2A in apoptotic signalling networks in human cancer cells. Curr Mol Med. 2012;12:268–87.PubMedCrossRef
40.
Zurück zum Zitat Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8:355–68.PubMedCrossRef Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell. 2005;8:355–68.PubMedCrossRef
41.
Zurück zum Zitat Lin QDWX, Wang P, Liu YY, Zhang LN, Li YF. Application of all-trans retinoic acid combining chemotherapy and As4S4 in the maintenance treatment of patients with acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2007;28:19–21.PubMed Lin QDWX, Wang P, Liu YY, Zhang LN, Li YF. Application of all-trans retinoic acid combining chemotherapy and As4S4 in the maintenance treatment of patients with acute promyelocytic leukemia. Zhonghua Xue Ye Xue Za Zhi. 2007;28:19–21.PubMed
Metadaten
Titel
Tetra-arsenic tetra-sulfide (As4S4) promotes apoptosis in retinoid acid -resistant human acute promyelocytic leukemic NB4-R1 cells through downregulation of SET protein
verfasst von
Yanfeng Liu
Pengcheng He
Feng Liu
Naicen Zhou
Xiaoyan Cheng
Lili Shi
Huachao Zhu
Jing Zhao
Yuan Wang
Mei Zhang
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1452-1

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.